Endo Open To Settlement In US Vasostrict Showdown

Eagle Strongly Suggested ‘At-Risk’ Launch Is Possible

 
• By Dean Rudge

Endo is leaving the door wide open to settle its patent-litigation showdown with Eagle Pharmaceuticals over Vasostrict (vasopressin), after Eagle said it was mulling an ‘at-risk’ launch.

Wooden_Gavel
“This paragraph IV litigation is obviously a very important area of focus for us,” Endo acknowledges • Source: Shutterstock

More from Generics

More from Products